



DISA Limited
(Company Registration No. 197501110N)
(Incorporated in the Republic of Singapore)
("Company" and together with its subsidiaries, the "Group")

APPOINTMENT OF DIRECTORS AND CHANGE IN SHAREHOLDINGS AT DIGITAL LIFE LINE PTE. LTD., A SUBSIDIARY OF DISA DIGITAL SAFETY PTE. LTD.

Further to the news release on the signing of licensing agreement between Digital Life Line Pte. Ltd. ("DLL"), National University of Singapore ("NUS") and Singapore Health Services Pte. Ltd. ("SingHealth") to commercialise new saliva-based COVID-19 antigen rapid test ("ART") kits released on 8 December 2021, the board of directors (the "Board") of the Company wishes to announce the following:

(1) Professor Soo Khee Chee, Dr. Guy Heathers and Mr. John Wong Weng Foo will be appointed as the directors of DLL ("DLL Directors") with effect from 29 December 2021

Professor Soo, who is one of the inventors of the new saliva-based COVID-19 ART technology, studied medicine in the University of Singapore and graduated in 1975. He did his surgical training in Sydney and then had his fellowship training in surgical oncology and head and neck surgery in London and New York. He returned to Singapore General Hospital in 1988 and has been there since. In 1993, he became the Head of the Department of Surgery and held that position for 11 years. He was for a period the Chairman of the NUS Department of Surgery. In 1997, he became the Founding Director of the National Cancer Centre Singapore and recently retired from that position after 20 years. He was also the Senior Vice Dean of Duke NUS Medical School and now continues to hold the Benjamin Sheares Professorship in Academic Medicine. He has just started his own surgical practice in Farrer Park Hospital.

In his career in Singapore spanning 30 years, he has trained numerous general surgeons, surgeons with interest in cancer surgery and head and neck surgery. In that period of time, he has the pleasure of seeing many of these specialties have become recognised as leading practitioners in their respective fields in Singapore and regionally.

He has been recognised as the pioneer and leading cancer surgeon in the country. He introduced complex surgery like peritonectomies for previously inoperable cancers in the abdominal cavity and major intraabdominal tumours including removal of invaded major blood vessels. In the field of head and neck surgery, he is recognised to have performed the most of complex operations for cancers in this region. He is also recognised for removal of limb soft tissue tumours. He also introduced isolated limb perfusion for the management of intransit metastases for skin tumours attempting to salvage limbs which would otherwise require amputations.

Professor Soo has won several national awards including Public Administration (Gold), National Outstanding Mentor and the President's Science and Technology Award. He is currently the Inaugural Benjamin Sheares Professor in Academic Medicine for Duke-Nus Medical School.

Dr. Guy Heathers is currently the Vice President of Business Development at Hummingbird Bioscience as well as consultant to a number of Singapore biotech companies and former Director of Technology Development at the National Cancer Centre, Singapore and Director of SingHealth Intellectual Properties office. Previously, Guy held a number of positions in the bioscience field in different continents, including CBO at Cancer Therapeutics CRC Pty Ltd, Melbourne Australia; CEO at Amaranth Medical Pte Ltd (Singapore), Gateway Capital Pty Ltd (Australia) and Biotech Research Ventures Pte Ltd (Singapore). Earlier in his career, he held positions of Chief Operating Officer, Cancer Research Ventures Ltd and Head of Business Development, Cancer Research

Campaign Technology Ltd. He started his business career with 7 years of drug discovery management at Hoffmann-La Roche in Nutley, NJ, USA, across a number of therapeutic areas. In addition to these roles, Guy has been instrumental in creating and developing over 20 biotech start-ups during his career, including Cyclacel (listed on NASDAQ), Kudos (bought by Astra Zeneca) and Enleofen (bought by Boehringer Ingelheim) as well as numerous multi-million dollar international licensing and collaboration deals in the biotechnology industry.

Mr. John Wong was a General Partner at General Atlantic Partners, LLC, a worldwide private equity firm, and the Group Managing Director for Hong Leong Corporation. Previously, he was also the Chairman of TSH Corporation Limited, Vice Chairman of China Yuchai Ltd, Managing Director of IBM Singapore, Sri Lanka and Brunei, a Trustee of Singapore Management University, and a Director of the Singapore Institute of Management, Asia Dekor Holdings Limited, Asia Dekor Pte Ltd and Goodpack Limited.

Mr. Wong holds an MBA from Brunel University (UK) and completed the Advanced Management Programme at the University of Hawaii.

Following the abovementioned appointments, with effect from 29 December 2021, the composition of the Board of DLL shall be as follows:

Dr. Soo Khee Chee, Chairman
 Dr. Guy Heathers
 Mr. John Wong Weng Foo
 Mr. Chng Weng Wah, Managing Director and CEO
 Mr. Han Yang Kwang

(2) Change in Shareholding Percentage of DLL

The Board wishes to announce that Disa Digital Safety Pte. Ltd. (“**DiSa**”), a wholly owned subsidiary of the Company, has transferred 5,500 shares, representing 11% of the total issued and paid-up capital of DLL, to DLL Directors, Professor Soo Khee Chee and Mr John Wong Weng Foo:

Transferee	No. of Shares Transferred	Subscription Price	Shareholding (%)
Professor Soo Khee Chee	3,000	S\$300.00	6%
John Wong Weng Foo	2,500	S\$250.00	5%

Following the above transfer, with effect from 29 December 2021, the composition of shareholders of DLL shall be as follows:

Name of Shareholder	No. of Shares Held	Shareholding (%)
DiSa	41,000	82%
Chng Weng Wah *	3,500	7%
Professor Soo Khee Chee	3,000	6%
John Wong Weng Foo	2,500	5%
Total	50,000	100%

* Chng Weng Wah is the Managing Director and Chief Executive Officer and substantial shareholder of the Company.

The above transfer is considered a non-discloseable transaction under Rule 1008 of the Catalyst Rules.

The value that the DLL Directors brings through their knowledge, insight and experiences is immensely important for the long term success of DLL’s business.

BY ORDER OF THE BOARD

Chng Weng Wah
Managing Director and Chief Executive Officer
29 December 2021

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Ong Hwee Li (Registered Professional, SAC Capital Private Limited)

Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

Telephone number: +65 6232 3210

About Digital Life Line Pte. Ltd.

DLL, a 82% owned subsidiary of Disa Digital Safety Pte. Ltd., is a Singapore-based company that deals with the manufacturing and distribution of saliva-based Antigen Rapid Test (ART) kits. Digital Life Line has signed tri-party licensing agreement with National University of Singapore ("**NUS**") and Singapore Health Services Pte. Ltd. ("**SingHealth**") on 8 December 2021 for the use of their new saliva-based COVID-19 ART technology. This technology was co-developed by SingHealth Duke-NUS Academic Medical Centre and the NUS.

About DiSa Digital Safety Pte. Ltd.

DiSa, a wholly-owned subsidiary of DISA Limited, is a Singapore-based technology solution provider that specializes in research and development of cutting-edge digital security solution ("**DiSa Asset Protection System**"). With its single scan technology and seamless integration, DiSa has been able to provide item level tracking and data with no disruption to the sales process. This technology is now protecting products and categories previously unachievable with traditional serialization methods, saving millions of dollars in prevented returns.

DiSa entered the US market in 2014 launching its Smart Solutions within the largest retailer in the world with a limited store test. After rigorous testing by the Loss Prevention Research Council, USA, DiSa rolled out its Smart Solutions nationwide in 2017.

About DISA Limited

DISA Limited (SGX: 532), is a publicly-traded company on the Singapore Catalist Stock Exchange. More information is available at <http://www.digital-safety.com>.